Nutrien
Nutrien's revenue rose 3.5% to $26.9 billion in fiscal 2025. Its operating margin was 13.9%, up from 7.2% a year earlier. Free cash flow was $2.1 billion, up 40.7%. It paid out $1.6 billion in dividends and buybacks, 76% of free cash flow. The diluted share count fell 1.6%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on capital is after-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Revenue and margins
Net income and earnings per share
From fiscal 2017 to 2025, earnings per share grew 36.4% a year and net income 27.4% a year, as buybacks cut the share count by 42%.
Returns on capital
Cash flow
Payouts and share count
Balance sheet
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 0.5 | 0.9 | 0.9 | 0.9 | 0.7 |
| Debt incl. finance leases | 9.6 | 10.7 | 11.2 | 11.5 | 10.7 |
| Net debt (negative means net cash) | 9.1 | 9.8 | 10.3 | 10.6 | 10.0 |
| Net debt to EBITDA | 1.4x | 0.8x | 2.1x | 2.5x | 1.6x |
| Debt to equity | 0.4x | 0.4x | 0.5x | 0.5x | 0.4x |
| Interest coverage | 9.7x | 20.8x | 3.4x | 2.4x | 5.0x |
| Current ratio | 1.1x | 1.1x | 1.2x | 1.1x | 1.3x |
| Quick ratio | 0.6x | 0.6x | 0.7x | 0.6x | 0.7x |
Piotroski F-score
The F-score counts how many of nine simple tests of profitability, funding and efficiency a company passed in a year (Piotroski, 2000). The more tests passed, the stronger the year: 8 or 9 is strong, 0 to 2 weak. Companies that report no gross profit are scored on the other eight.
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Pass | Pass | Pass |
| Cash from operations is positive | Pass | Pass | Pass |
| Return on assets rose | Fail | Fail | Pass |
| Cash from operations exceeds net income | Pass | Pass | Pass |
| Debt fell relative to assets | Fail | Fail | Pass |
| Current ratio rose | Pass | Fail | Pass |
| Share count didn't rise | Pass | Pass | Pass |
| Gross margin rose | Fail | Fail | Pass |
| Revenue rose relative to assets | Fail | Fail | Pass |
| F-score | 5 of 9 | 4 of 9 | 9 of 9 |
| Accruals ratio | −7.1% | −5.5% | −3.3% |
Compare
Put Nutrien side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| Nutrien | FY25 | 3.5% | 13.9% | 7.9% | 8.0% | 1.6x | 9 | |
| Corteva | FY25 | 2.9% | — | 16.2% | 5.8% | −0.6x | 8 | Compare |
| Mosaic | FY25 | 8.4% | 6.8% | −4.4% | 2.5% | 2.5x | 8 | Compare |
| CF Industries | FY25 | 19.3% | 32.5% | 25.4% | 20.6% | 0.4x | 8 | Compare |
| FMC | FY25 | −18.3% | −47.0% | −3.0% | −19.6% | — | 2 | Compare |
9 years of figures
| Fiscal year | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|
| Income statement | |||||||||
| Revenue | 4.5 | 19.6 | 20.1 | 20.9 | 27.7 | 37.9 | 29.1 | 26.0 | 26.9 |
| Revenue growth | — | 331.9% | 2.3% | 4.1% | 32.5% | 36.7% | −23.3% | −10.6% | 3.5% |
| Gross profit | 0.7 | 5.4 | 5.5 | 5.2 | 9.4 | 15.4 | 8.5 | 7.5 | 8.3 |
| Research and development | — | — | — | — | — | — | — | — | — |
| Operating income | 0.2 | 0.4 | 1.9 | 0.9 | 4.8 | 10.8 | 2.7 | 1.9 | 3.7 |
| Net income | 0.3 | 3.6 | 1.0 | 0.5 | 3.2 | 7.7 | 1.3 | 0.7 | 2.3 |
| Diluted EPS (US$) | 0.39 | 5.72 | 1.70 | 0.81 | 5.52 | 14.18 | 2.53 | 1.36 | 4.66 |
| Diluted shares (millions) | 840 | 625 | 583 | 570 | 571 | 540 | 497 | 494 | 486 |
| Cash flow | |||||||||
| Cash from operations | 1.2 | 2.1 | 3.7 | 3.3 | 3.9 | 8.1 | 5.1 | 3.5 | 4.0 |
| Capital expenditure | 0.7 | 1.4 | 1.7 | 1.4 | 1.8 | 2.3 | 2.4 | 2.0 | 1.9 |
| Free cash flow | 0.6 | 0.6 | 1.9 | 1.9 | 2.1 | 5.9 | 2.7 | 1.5 | 2.1 |
| Dividends paid | 0.3 | 1.0 | 1.0 | 1.0 | 1.0 | 1.0 | 1.0 | 1.1 | 1.1 |
| Share buybacks | 0.0 | 1.8 | 1.9 | 0.2 | 1.0 | 4.5 | 1.0 | 0.2 | 0.6 |
| Acquisitions | 0.0 | 0.4 | 0.9 | 0.2 | 0.1 | 0.4 | 0.2 | 0.0 | 0.0 |
| Stock-based compensation | 0.0 | 0.1 | 0.1 | 0.1 | 0.2 | 0.1 | −0.0 | 0.0 | 0.2 |
| Balance sheet at fiscal year end | |||||||||
| Cash and short-term investments | 0.1 | 2.3 | 0.7 | 1.5 | 0.5 | 0.9 | 0.9 | 0.9 | 0.7 |
| Debt incl. finance leases | 4.4 | 9.2 | 10.0 | 10.2 | 9.6 | 10.7 | 11.2 | 11.5 | 10.7 |
| Total assets | 17.0 | 45.5 | 46.8 | 47.2 | 50.0 | 54.6 | 52.7 | 51.8 | 52.3 |
| Total liabilities | 8.7 | 21.1 | 23.9 | 24.8 | 26.3 | 28.7 | 27.5 | 27.4 | 26.9 |
| Shareholders' equity | 8.3 | 24.4 | 22.9 | 22.4 | 23.7 | 25.8 | 25.2 | 24.4 | 25.3 |
| Margins and ratios | |||||||||
| Gross margin | 15.3% | 27.5% | 27.4% | 25.1% | 34.0% | 40.7% | 29.2% | 29.0% | 31.1% |
| Operating margin | 4.6% | 2.1% | 9.3% | 4.3% | 17.2% | 28.5% | 9.4% | 7.2% | 13.9% |
| Net margin | 7.2% | 18.2% | 4.9% | 2.2% | 11.4% | 20.2% | 4.3% | 2.6% | 8.4% |
| Free cash flow margin | 12.6% | 3.3% | 9.6% | 9.1% | 7.6% | 15.5% | 9.1% | 5.8% | 7.9% |
| Return on capital | — | 1.5% | 4.4% | 2.8% | 11.4% | 23.7% | 5.1% | 3.2% | 8.0% |
| Return on equity | — | 21.8% | 4.2% | 2.0% | 13.7% | 31.0% | 4.9% | 2.7% | 9.1% |
| Return on assets | — | 11.4% | 2.1% | 1.0% | 6.5% | 14.7% | 2.3% | 1.3% | 4.3% |
| Net debt to EBITDA | — | — | 148.6x | 3.0x | 1.4x | 0.8x | 2.1x | 2.5x | 1.6x |